Medtronic 8-K
PositiveDeal completedLeadership changeExecutive payShareholder vote
MiniMed separation completed after the exchange offer was 5.4x subscribed.
Filed 2026-10-19 16:23 ET
- 5.02 Officer/director change
- 5.07 Shareholder Vote Results
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
MiniMed separation completion, Medtronic President appointment and annual meeting results. Medtronic’s exchange offer settled and the separation is complete; the offer for Medtronic shares was 5.4x subscribed. Michael Marinaro became President, Medtronic, effective 10/14/2026, retaining his existing responsibilities and adding oversight of Greater China. Shareholders elected all 12 director nominees, ratified the auditor, approved executive compensation, and approved the remaining proposals.
Key Figures
- Exchange offer: Medtronic exchanged its remaining 252,813,348 MiniMed shares.
- Marinaro compensation: FY2027 annual base salary of $1.0M; target annual incentive remains 100% of base salary.
- Supplemental FY2027 long-term incentive awards, with an aggregate target value of ≈$3.25M, to be granted 11/02/2026: performance share units valued at $1.625M, stock options with a $0.975M grant-date value, and restricted stock units valued at $0.65M. Performance share units vest 4/27/2029 based on FY2027–FY2029 performance; options vest in four equal annual installments beginning 8/3/2027 and have a 10-year term; restricted stock units vest 8/3/2029.
The summary is written by an AI model reading the filing.
Model 005 · prompt v95 · 2026-10-19 22:34:03Z